Welcome to our dedicated page for FSTX news (Ticker: FSTX), a resource for investors and traders seeking the latest updates and insights on FSTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FSTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FSTX's position in the market.
F-star Therapeutics (NASDAQ: FSTX) has received U.S. Patent No. 11,033,569 for its second-generation STING agonist, SB 11285, ensuring patent protection until July 2037. This development coincides with encouraging interim results from an ongoing clinical trial (NCT04096638) assessing the drug's safety and efficacy, both alone and in combination with atezolizumab, in patients with advanced solid tumors. SB 11285 showcases enhanced delivery to difficult tumors and demonstrates promising preclinical results, including significant tumor regression.
F-star Therapeutics (NASDAQ: FSTX) announced a collaboration with MSD to evaluate the combination of its bispecific antibody FS120 with KEYTRUDA in clinical trials. The combination aims to improve treatment outcomes for patients with advanced cancer. FS120, targeting CD137 and OX40, is currently in a Phase 1 clinical trial initiated in December 2020. The partnership signifies a crucial development as it moves toward assessing the clinical efficacy of this combination therapy, with updates expected later this year and plans to initiate combination cohorts in H2 2022.
F-star Therapeutics (NASDAQ: FSTX) announced it will release earnings for the quarter ending June 30, 2021, on August 12, 2021, before market open. The company will host an investor conference call at 9:00 a.m. EST the same day to discuss financial results and corporate updates. Interested parties can join via a live webcast or by phone. F-star focuses on developing tetravalent bispecific antibodies aimed at improving cancer therapy by blocking tumor immune evasion and aims to create best-in-class drug candidates.
F-star Therapeutics (NASDAQ: FSTX) has provided an interim update on its first-in-human dose-escalation study of SB 11285, a novel STING agonist aimed at treating advanced solid tumors. The study is assessing the safety and efficacy of SB 11285, administered intravenously alone and in combination with atezolizumab. Initial findings indicate that SB 11285 is well tolerated, with pharmacokinetics aligning with expectations. The company reported early evidence of disease control and plans to share further updates in 2022. The trial continues to explore dose escalations beyond initial agreements.
F-star Therapeutics (NASDAQ: FSTX) announced its participation in the upcoming Ladenburg Thalmann Healthcare Conference and William Blair Biotech Focus Conference. The events will be held virtually on July 13 and July 14, 2021, respectively. F-star's CEO, Eliot Forster, will engage in a fireside chat at the Ladenburg conference, while CSO, Neil Brewis, will participate in a panel discussion at the William Blair conference. These conferences aim to enhance F-star's visibility within the biopharmaceutical sector.
F-star Therapeutics (NASDAQ: FSTX) has entered an exclusive licensing agreement with AstraZeneca to develop next-generation STING inhibitors. AstraZeneca will manage all research and commercialization, while F-star retains rights to its STING agonists in clinical development. This deal could yield F-star up to $12 million in upfront payments and over $300 million in milestones, along with royalties. The agreement aims to leverage the potential of STING inhibitors in treating cancer and immune-mediated diseases.
F-star Therapeutics (NASDAQ: FSTX) reported its first quarter 2021 financial results, highlighting significant achievements and financial updates. The company successfully closed a $65 million public offering, strengthening its balance sheet for future milestones. R&D expenses increased to $7.3 million, reflecting growth in clinical activities. The net loss for the quarter was $9.9 million, compared to a loss of $7.2 million in Q1 2020. Key developments include LAG-3 co-targeting validation and the expansion of the FS118 patent portfolio.
F-star Therapeutics (NASDAQ: FSTX) announced an upcoming investor conference call scheduled for May 17, 2021, at 9:00 a.m. EST. The call will cover the financial results for the quarter ending March 31, 2021, along with a corporate update. Participants can join via a live webcast on the company’s website or by phone using provided international numbers. The conference call will also be available for replay for 90 days. F-star focuses on developing tetravalent bispecific antibodies aimed at improving cancer treatment outcomes.
F-star Therapeutics, Inc. (Nasdaq: FSTX) announced a public offering of 9,285,715 shares at $7.00 per share, totaling $65 million in expected proceeds. The offering is set to close around May 11, 2021, pending customary conditions. Proceeds will fund working capital, clinical trials, and research and development. The underwriters also have a 30-day option for an additional 1,392,857 shares. SVB Leerink is the sole bookrunning manager. This offering aims to enhance F-star's capacity in developing next-generation immunotherapies for cancer.
F-star Therapeutics, Inc. (FSTX) has initiated an underwritten public offering of its common stock, with a potential underwriter option for an additional 15% of shares. The company aims to utilize the proceeds for working capital, clinical trials, research and development, and corporate purposes. The offering is subject to market conditions, and there's no guarantee on its completion or terms. SVB Leerink is managing the offering, which follows a previously effective shelf registration statement.
